MA32984B1 - Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire - Google Patents

Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire

Info

Publication number
MA32984B1
MA32984B1 MA34038A MA34038A MA32984B1 MA 32984 B1 MA32984 B1 MA 32984B1 MA 34038 A MA34038 A MA 34038A MA 34038 A MA34038 A MA 34038A MA 32984 B1 MA32984 B1 MA 32984B1
Authority
MA
Morocco
Prior art keywords
cardiovascular disease
women
treatment
risk
vaginal atrophy
Prior art date
Application number
MA34038A
Other languages
Arabic (ar)
English (en)
Inventor
Fernández Álvaro Acebrón
Lousame Dolores Blanco
Del Prado Jaime Moscoso
Magro Concepción Nieto
Original Assignee
Italfarmaco Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32984(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Sa filed Critical Italfarmaco Sa
Publication of MA32984B1 publication Critical patent/MA32984B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE L'UTILISATION D'ESTRIOL DANS LA PRÉPARATION D'UNE FORMULATION PHARMACEUTIQUE POUR ADMINISTRATION VAGINALE, AYANT LA CAPACITÉ D'AUTO-LIMITER L'ABSORPTION D'ESTRIOL. LADITE PRÉPARATION VISE À LA PRÉVENTION ET/OU AU TRAITEMENT DE L'ATROPHIE UROGÉNITALE CHEZ DES FEMMES PRÉSENTANT UNE PROBABILITÉ ÉLEVÉE D'ÊTRE ATTEINTES D'UNE PATHOLOGIE CARDIOVASCULAIRE, OU DE SOUFFRIR OU D'AVOIR SOUFFERT D'UNE PATHOLOGIE CARDIOVASCULAIRE.
MA34038A 2008-12-19 2009-08-07 Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire MA32984B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803623A ES2344675B1 (es) 2008-12-19 2008-12-19 Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
PCT/EP2009/060304 WO2010069621A1 (fr) 2008-12-19 2009-08-07 Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire

Publications (1)

Publication Number Publication Date
MA32984B1 true MA32984B1 (fr) 2012-01-02

Family

ID=41050933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34038A MA32984B1 (fr) 2008-12-19 2009-08-07 Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire

Country Status (23)

Country Link
US (1) US8835414B2 (fr)
EP (1) EP2376086B1 (fr)
JP (1) JP2012512818A (fr)
KR (1) KR101734380B1 (fr)
CN (1) CN102325533A (fr)
CA (1) CA2747314C (fr)
CL (1) CL2011001493A1 (fr)
CO (1) CO6382128A2 (fr)
CY (1) CY1120971T1 (fr)
DK (1) DK2376086T3 (fr)
EC (1) ECSP11011211A (fr)
ES (2) ES2344675B1 (fr)
HR (1) HRP20182022T1 (fr)
HU (1) HUE040394T2 (fr)
LT (1) LT2376086T (fr)
MA (1) MA32984B1 (fr)
MX (1) MX2011006696A (fr)
PE (1) PE20120496A1 (fr)
PL (1) PL2376086T3 (fr)
PT (1) PT2376086T (fr)
RU (1) RU2555752C2 (fr)
SI (1) SI2376086T1 (fr)
WO (1) WO2010069621A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016110839A1 (fr) * 2015-01-05 2016-07-14 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Nanoparticules et procédés pour leur préparation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1866M (fr) 1961-04-07 1963-06-17 Vismara Francesco Spa Nouveaux éthers des hormones oestrogenes.
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
WO1991006289A1 (fr) 1989-10-31 1991-05-16 Watson Laboratories, Inc. Support muco-adhesif servant a liberer un agent therapeutique
DK0431719T3 (da) 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5741525A (en) 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
IT1275816B1 (it) 1995-10-27 1997-10-17 Montefarmaco Spa Composizioni farmaceutiche solide per uso vaginale
AU714797B2 (en) 1996-06-14 2000-01-13 Mcneil-Ppc, Inc. Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof
IT1284874B1 (it) 1996-08-02 1998-05-22 Farmigea Spa Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
AP1209A (en) 1996-11-14 2003-09-30 Lipomedica Ehf Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglceride derivatives thereof for treating of mucosa infections.
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
WO2000050078A1 (fr) 1999-02-26 2000-08-31 Chiron Corporation Utilisation de systemes bioadhesifs et d'adjuvants pour l'administration mucosale d'antigenes
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
WO2001028515A1 (fr) 1999-10-22 2001-04-26 Líf-Hlaup ehf. Bio-Gels Pharmaceuticals Inc. Composition pharmaceutique pour le traitement de l'ulceration et/ou erosion epitheliale des muqueuses
SK288129B6 (sk) * 2000-01-18 2013-10-02 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormonal substitution treatment
DE60143360D1 (de) 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
JP3655846B2 (ja) 2001-06-27 2005-06-02 埼玉日本電気株式会社 Ｃｄｍａ移動通信システム、及びその呼切断防止方法
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
BRPI0614625A2 (pt) 2005-08-12 2011-04-12 Drugtech Corp composição farmacêutica que compreende pelo menos um composto estrogênico, sistema de distribuição de estrogênio vaginal, uso de uma composição e kit que compreende uma pluralidade de cremes vaginais
US20090124584A1 (en) 2005-12-16 2009-05-14 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
KR20090031847A (ko) * 2006-01-20 2009-03-30 피어 트리 파머슈티칼스 인코포레이티드 위축성 질염을 치료하는 방법
EP1872775A1 (fr) * 2006-06-29 2008-01-02 Polichem S.A. Emploi d'une matrice hydrophile contenant un dérivé polyacrylique, un éther de cellulose et un désintégrant, pour la production d'un médicament pour le traitement des troubles génitales d'une femme
WO2008089405A1 (fr) 2007-01-19 2008-07-24 Neurosci, Inc. Composition d'hormones multiples administrée par voie vaginale en une seule crème
ES2310968B1 (es) * 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.

Also Published As

Publication number Publication date
CN102325533A (zh) 2012-01-18
RU2011127702A (ru) 2013-01-27
WO2010069621A8 (fr) 2011-07-21
ES2344675A1 (es) 2010-09-02
RU2555752C2 (ru) 2015-07-10
HUE040394T2 (hu) 2019-03-28
SI2376086T1 (sl) 2019-02-28
WO2010069621A1 (fr) 2010-06-24
CA2747314C (fr) 2017-04-18
US20110312929A1 (en) 2011-12-22
ES2344675B1 (es) 2011-04-28
CY1120971T1 (el) 2019-12-11
MX2011006696A (es) 2011-07-28
JP2012512818A (ja) 2012-06-07
DK2376086T3 (en) 2018-12-10
LT2376086T (lt) 2019-01-10
EP2376086A1 (fr) 2011-10-19
PL2376086T3 (pl) 2019-05-31
ECSP11011211A (es) 2011-08-31
EP2376086B1 (fr) 2018-09-19
KR101734380B1 (ko) 2017-05-11
KR20110108358A (ko) 2011-10-05
US8835414B2 (en) 2014-09-16
CO6382128A2 (es) 2012-02-15
PT2376086T (pt) 2018-12-18
ES2707873T3 (es) 2019-04-05
CL2011001493A1 (es) 2012-01-13
HRP20182022T1 (hr) 2019-01-25
PE20120496A1 (es) 2012-05-04
CA2747314A1 (fr) 2010-06-24

Similar Documents

Publication Publication Date Title
MA30085B1 (fr) Traitement du diabete de type 2 avec une association d'un inhibiteur de dpiv et de metformine ou d'une thiazolidinedione
MA47399B1 (fr) Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MA33046B1 (fr) Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
MA27802A1 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies.
MA29600B1 (fr) Utilisation de sanglifehrine dans le virus de l'hepatite c
MA29236B1 (fr) Prevention et traitement de troubles thromboemboliques
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
TNSN08397A1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
TNSN08428A1 (fr) NOUVELLE FORME d'ADMINISTRATION DU RACECADOTRIL
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
MA62910A1 (fr) Inhibiteurs de line-1 pour traiter des maladies du snc et des maladies systémiques
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
MA29722B1 (fr) Schema posologique pour le prasugrel
MA28121A1 (fr) Agent immunothérapique utile pour le traitement combiné de la tuberculose en association avec d'autres médicaments
MA27590A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA32984B1 (fr) Traitement de l'atrophie vaginale chez des femmes souffrant d'un risque de pathologie cardiovasculaire